Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that the SAAD-41 is a validated tool for assessing psychosocial outcomes in individuals with alopecia areata, showing strong correlations with established measures of quality of life and coping.

This study identified associations between alopecia areata and posttraumatic stress disorder, obesity, and alcohol use, reinforcing the need for psychiatric and alcohol use screening in these patients.

This article reviews the role of the National Alopecia Areata Foundation in promoting research and collaboration to find treatments or a cure for alopecia areata and reports no clinical results.

This article discusses the characteristics of alopecia areata but reports no new research results.

This literature review highlights challenges in managing alopecia areata in the Middle East and Africa, noting significant regional gaps in data, treatment guidelines, and public awareness that impede patient care and emphasize the need for improved support and resources.

This study introduces diagnostic and therapeutic algorithms tailored for tailored management of alopecia areata based on patient-specific factors like age, disease severity, and quality of life.

The excimer laser may help hair regrow in alopecia areata patients.

This study found that anagen stage protein homogenates and specific epitopes from melanogenesis proteins activated CD8 T cells, suggesting alopecia areata is an anagen-specific disease.

This study observed that patients with autism spectrum disorder have a higher risk of developing alopecia areata compared to those without ASD, suggesting a possible link between the two conditions.

This abstract contains no research findings; it outlines website features and access options for the JAMA network's publications.

This study found a significant psychosocial and occupational burden on caregivers of adolescents with alopecia areata in Australia, impacting their mental and emotional well-being and emphasizing the need to recognize the broader effects of the condition beyond the patients themselves.

This study found that early initiation of phototherapy is an effective treatment strategy for certain subtypes of AA, particularly in older patients and those with a shorter disease duration.

This study found that alopecia areata is significantly associated with thyroid autoimmunity, but not with clinical or subclinical thyroid disease, in the Pakistani population.

This source evaluates the clinical effectiveness of 308 nm monochromatic excimer phototherapy in treating moderate-to-severe alopecia areata, noting that both laser and lamp methods show promise without significant risks.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

This study reported that an ATRA-loaded nanostructured lipid carrier gel (ATRA-NLC-Gel) improved symptoms of alopecia areata in mice by enhancing transdermal drug delivery, reducing skin irritation, and promoting hair regrowth through targeted follicle enrichment and pathway activation.

In this study, PA-011 extract was reported to promote hair growth and alleviate alopecia areata symptoms in mice by reducing skin inflammation and modulating skin microbiota.

This report highlights a case of a 35-year-old man developing alopecia universalis following alemtuzumab treatment for multiple sclerosis, suggesting potential links between this medication and drug-induced alopecia areata, though the genetic overlap of the conditions may also play a role.

This review identified evidence gaps in NHIRD, emphasizing the lack of validated diagnostic criteria and the need for further research on ocular and systemic comorbidities associated with AA to enhance patient care and treatment strategies.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This review discusses recent advances in understanding the pathogenesis of autoimmune alopecia areata and reports no new clinical results; it highlights potential for developing more effective treatments.

This abstract introduces baricitinib as an approved treatment for adults with severe alopecia areata in the US, Europe, and Japan, but does not report any specific study results or findings.

This study utilized 3D ultra-high frequency ultrasound to effectively detect different disease phases of alopecia areata by visualizing hair follicle structures and identifying unique pathological signs, offering a promising non-invasive diagnostic tool that surpasses conventional methods.

In this observational study, men with early onset androgenic alopecia exhibited a statistically significant correlation with more severe forms of coronary artery disease compared to those without the condition.

This study found that patients with alopecia areata had a higher incidence rate of herpes simplex infection compared to matched individuals without the condition.

This study established consensus criteria for classifying alopecia areata severity, aiding clinicians in accurate diagnosis and treatment planning.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

In this retrospective case-control study, researchers reported that patients with alopecia areata had significantly increased odds of venous thromboembolism compared to matched controls, suggesting a potential association between alopecia areata and risk of VTE.